Navigation Links
The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene
Date:7/31/2014

CHICAGO, July 31, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Biogen (Nasdaq: BIIB-Free Report), Gilead (Nasdaq: GILD-Free Report), Puma Biotechnology (NYSE: PBYI-Free Report), AbbVie (NYSE: ABBV-Free Report) and Celgene (Nasdaq: CELG-Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday's Analyst Blog:

Biotech Stock Roundup

It was a busy week in the biotech sector with quite a few major companies reporting second quarter earnings. Outperformers included companies like Biogen (Nasdaq: BIIB-Free Report) and Gilead (Nasdaq: GILD-Free Report) – both reported impressive numbers that sailed past expectations.

Meanwhile, a company that stood out last week among the outperformers is Puma Biotechnology (NYSE: PBYI-Free Report) thanks to positive top-line data on its late-stage experimental cancer treatment.

Recap of the Week's Most Important Stories

1. Gilead's second quarter results were way above expectations thanks to the continued impressive performance of hepatitis C virus (HCV) treatment, Sovaldi. Sovaldi contributed $3.48 billion to second quarter revenues, accounting for more than half of total revenues in the reported quarter. For the first time, Gilead provided revenue guidance including the impact of Sovaldi.

Meanwhile, in addition to reporting impressive second quarter results, Gilead could very well have another blockbuster in its hands in the form of Zydelig which gained FDA approval for three types of cancer (Read more: Gilead Crushes Q2 Earnings Estimates as Sovaldi Sales Soar).

2. Another biotech company that came out with results that shot past expectations by a wide margin is Biogen. Biogen's results too were driven by the impressive performance of one of its more recent offerings – oral multiple sclerosis (MS) treatment Tecfidera.

According to Biogen, Tecfidera, which is already the leading oral MS therapy in the U.S., is on track to be the leading MS therapy in the U.S. Biogen upped its earnings and revenue guidance significantly – this is the second time this year that the company raised its outlook (Read more: Biogen's Q2 Earnings Surpass Expectations, Tecfidera Shines).

3. AbbVie (NYSE: ABBV-Free Report) also reported strong results with Humira remaining the growth driver. With AbbVie's dependence on Humira having been a source of concern, the upcoming acquisition of UK-based Shire bodes well for the company. This acquisition will not only lead to lower taxes, AbbVie's product portfolio and pipeline will also get a boost (Read more: AbbVie Q2 Earnings Top on Humira Sales, Shire In Focus).

4.Celgene's (Nasdaq: CELG-Free Report) second quarter results were also better-than-expected and the company raised its guidance as well. The key growth driver was cancer drug, Revlimid, which brought in sales of $1.2 billion (Read more: Celgene Beats Q2 Earnings Estimates on Strong Revlimid Sales).

5. Puma Biotechnology's shares skyrocketed a whopping 295% on positive data from late-stage study on its experimental breast cancer treatment, PB272 (neratinib). A 33% improvement in disease free survival was observed compared to placebo. With the positive data, Puma is in a position to file for approval in the first half of 2015 (Read more: Puma Biotech Surges on Positive Results on Neratinib).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on BIIB - FREE

Get the full Report on GILD - FREE

Get the full Report on PBYI - FREE

Get the full Report on ABBV - FREE

Get the full Report on CELG - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com 
http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO


'/>"/>
SOURCE Zacks Investment Research, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
2. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
3. Zacks Sell List Highlights: J.C. Penney, Spirit AeroSystems Holdings, The New York Times and Jazz Pharmaceuticals
4. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
5. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
6. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
7. Zacks Investment Ideas feature highlights: PharMerica, First Defiance Financial, American Railcar Industries and Big 5 Sporting Goods
8. Zacks.com featured expert Kevin Matras highlights: Core Laboratories NV, Invesco Ltd., Medtronic, Inc., Willbros Group Inc. and WuXi PharmaTech Inc.
9. The Zacks Analyst Blog Highlights: Exxon Mobil, Statoil, Chevron, Braskem and Cubist Pharmaceuticals
10. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
11. The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... 30, 2016 Eye expert s ... babies to seek an eye examination ...   Moorfields Eye Hospital Dubai, the first ... London , has identified premature babies as a special concern ... their particular vulnerability to retinopathy of prematurity (ROP). ROP is a ...
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharma company focused on the highly lucrative ... a substantial pipeline of potential first-in-class or best-in-class ... are in development with strategic partners. HCM,s profitable ... fast-growing domestic market. We expect progress of the ...
(Date:5/26/2016)... , May 26, 2016 According to ... Waste Management Market - U.S. Industry Analysis, Size, Share, Growth, ... market in the U.S. was valued at US$ 5.89 Bn ... of 3.4% from 2015 to 2023 to reach US$ 7.99 ... of current and emerging needle free drug delivery devices and ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... ... Houston Healthconnect’s (Healthconnect) regional health information exchange, which enables physicians at SJMC’s two ... their patients from other participating organizations in the exchange. SJMC’s membership in the ...
(Date:5/31/2016)... ... May 31, 2016 , ... CallTrackingMetrics's ... advertising campaigns, to monitor the performance of sales and support staff, and to ... revenue. The software allows customers to record, transcribe, route, document, and report on ...
(Date:5/31/2016)... ... ... The Global Wellness Summit (GWS), an annual conference for international ... travel, spa and beauty in Europe. The organization asked its partner experts in Europe ... researchers - to forecast where wellness is headed in Europe. Predictions range from European ...
(Date:5/31/2016)... ... 2016 , ... Interest is on the rise for using the CRISPR-Cas9 system ... for RNAi hit validation. A key reason may be that high-throughput synthesis—combined with a ... RNA (crRNA) collections in arrayed formats. , Arrayed crRNA screens have ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Dr. Charles A. ... Dentistry of New Jersey in the class of 1986, where he graduated in the ... at his current location in Livingston since 1989. He has been a member in ...
Breaking Medicine News(10 mins):